Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.67 -0.6%	$1.78	$0.99 ▼ $7.46	$85.25M	2.7	1.68 million shs	622,840 shs
DARE Dare Bioscience	$2.52 +0.8%	$2.80	$2.11 ▼ $9.19	$22.13M	1.14	386,489 shs	597,554 shs
EXOZ eXoZymes	$9.25	$12.23	$8.50 ▼ $23.99	$77.40M	N/A	11,602 shs	1,872 shs
JMAC Maxpro Capital Acquisition	$6.45 +7.3%	$6.16	$7.50 ▼ $19.22	$86.61M	0.01	74,040 shs	6,147 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-0.59%	-3.45%	-9.92%	+52.73%	-77.78%
DARE Dare Bioscience	-4.58%	+4.60%	-13.94%	-13.79%	-28.16%
EXOZ eXoZymes	-2.63%	-7.68%	-25.40%	-14.67%	+924,999,900.00%
JMAC Maxpro Capital Acquisition	+4.70%	-6.68%	-7.17%	+2.04%	+2,875.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.9536 of 5 stars	3.5	4.0	0.0	0.0	3.1	0.8	0.6
DARE Dare Bioscience	1.8616 of 5 stars	3.3	3.0	0.0	0.0	3.3	0.0	0.0
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	756.30% Upside
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	367.84% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest DARE, EXOZ, CABA, and JMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
DARE Dare Bioscience	$10K	2,270.03	N/A	N/A	($0.69) per share	-3.72
EXOZ eXoZymes	$70K	1,106.04	N/A	N/A	$1.25 per share	7.40
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	N/A	N/A	-8.14%	8/11/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest DARE, EXOZ, CABA, and JMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	DARE Dare Bioscience	-$0.55	N/A	N/A	N/A	$0.14 million	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/12/2025	Q1 2025	EXOZ eXoZymes	N/A	-$0.22	N/A	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	3.96	3.96
DARE Dare Bioscience	N/A	0.56	0.56
EXOZ eXoZymes	N/A	6.52	6.52
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
DARE Dare Bioscience	6.70%
EXOZ eXoZymes	N/A
JMAC Maxpro Capital Acquisition	73.18%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
DARE Dare Bioscience	4.00%
EXOZ eXoZymes	72.41%
JMAC Maxpro Capital Acquisition	19.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
EXOZ eXoZymes	29	8.37 million	2.31 million	N/A
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable

DARE, EXOZ, CABA, and JMAC Headlines

Recent News About These Companies

Maxpro Capital Acquisition (NASDAQ:JMAC) Shares Up 4.9% - Still a Buy?

July 11, 2025 | americanbankingnews.com

Maxpro Capital Acquisition (NASDAQ:JMAC) Shares Up 4.9% - Here's What Happened

July 11, 2025 | marketbeat.com

Maxpro Capital Acquisition (NASDAQ:JMAC) Stock Price Down 1.8% - Here's What Happened

June 19, 2025 | marketbeat.com

Denali Capital Acquisition Corp Ordinary Shares - Class A

May 23, 2024 | morningstar.comM

Denali Capital Acquisition Corp Ordinary Shares - Class A DECA Stock Quote

July 21, 2023 | morningstar.comM

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

June 6, 2023 | finance.yahoo.com

Maxpro Capital Acquisition Corp

April 5, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, EXOZ, CABA, and JMAC Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.67 -0.01 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+0.90%)

As of 07:50 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Dare Bioscience NASDAQ:DARE

$2.52 +0.02 (+0.80%)

Closing price 04:00 PM Eastern

Extended Trading

$2.52 0.00 (0.00%)

As of 07:57 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

eXoZymes NASDAQ:EXOZ

$9.25 0.00 (0.00%)

As of 10:13 AM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Maxpro Capital Acquisition NASDAQ:JMAC

$6.45 +0.44 (+7.32%)

As of 07/17/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time